QIAGEN Acquires Enzymatics Enzyme Solutions Unit, a Leading Enabler of NGS Applications PR Newswire HILDEN, Germany and BEVERLY, Massachusetts, January 11, 2015 HILDEN , Germany and BEVERLY, Massachusetts , January 11, 2015 /PRNewswire/ — Enzymatics products used in 80% of all global NGS sequencing reactions Strengthens QIAGEN’s universal NGS product offering and strategy to offer complete NGS workflows from sample to insight Adds comprehensive R&D, manufacturing, formulation and analytical capabilities in enzymology Strategic partnership formed with ArcherDX, including technology and distribution rights to proprietary Archer NGS panel technology QIAGEN reaffirms fourth-quarter and full-year 2014 adjusted net sales guidance; charges to be taken related to acquisition and other restructuring activities QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Prime Standard QIA) today announced the acquisition of the Enzyme Solutions Unit of Enzymatics, a world leader in the development, manufacturing, and OEM supply of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare. Enzymatics, a privately-held U.S […]